Trials / Completed
CompletedNCT01648517
Genotype-Driven Treatment of Advanced Non-small Cell Lung Cancer Based on mRNA Expression of ERCC1 & RRM1 as First-line Chemotherapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Yonsei University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective phase II trial, in patients with unresectable or metastatic NSCLC using chemotherapy regimens which will be defined according to the mRNA expression of ERCC1 and RRM1 of the tumor cells.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | chemotherapy | A1: docetaxel 60mg/m2 on Day 1 vinorelbine 20mg/m2 on Day 1 and Day 8 (DV) A2: gemcitabine 1000mg/m2 on Day 1 vinorelbine 25mg/m2 on Day 1 and Day 8 (GV) A3: docetaxel 75mg/m2 on Day 1 carboplatin AUC5 on Day 1 (DC) A4: gemcitabine 1000mg/m2 on Day 1 and 8 carboplatin AUC5 on Day 1 (GC) |
| DRUG | chemotherapy | Drug: Docetaxel 75mg/m2 IV on Day 1 Drug: Carboplatin AUC5 IV on Day 1 |
Timeline
- Start date
- 2012-07-27
- Primary completion
- 2015-06-30
- Completion
- 2015-06-30
- First posted
- 2012-07-24
- Last updated
- 2017-11-28
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01648517. Inclusion in this directory is not an endorsement.